These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 15073809)

  • 1. Prescription drug utilization following patient co-payment changes in Australia.
    McManus P; Donnelly N; Henry D; Hall W; Primrose J; Lindner J
    Pharmacoepidemiol Drug Saf; 1996 Nov; 5(6):385-92. PubMed ID: 15073809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
    Chen LC; Schafheutle EI; Noyce PR
    Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly.
    Liu SZ; Romeis JC
    Health Policy; 2004 Jun; 68(3):277-87. PubMed ID: 15113639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
    Robinson M; Rowett D; Leverton A; Mabbott V
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):659-64. PubMed ID: 19548222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of decentralization on health services in Uganda: a look at facility utilization, prescribing and availability of essential drugs.
    Anokbonggo WW; Ogwal-Okeng JW; Obua C; Aupont O; Ross-Degnan D
    East Afr Med J; 2004 Feb; Suppl():S2-7. PubMed ID: 15125109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaco-therapeutic evaluation of medical treatments of adult autistics and multi-handicapped patients in a public mental health unit].
    Armand-Branger S; Poisson N; Gaudoneix-Taïeb M; Ramos O
    Encephale; 2009 Sep; 35(4):370-6. PubMed ID: 19748374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician payment 2008 for interventionalists: current state of health care policy.
    Manchikanti L; Giordano J
    Pain Physician; 2007 Sep; 10(5):607-26. PubMed ID: 17876359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000.
    Al Khaja KA; Sequeira RP
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):741-8. PubMed ID: 16342299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
    Sullivan PW; Nair KV; Patel BV
    Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of outpatient co-payment policy on healthcare usage by the elderly in Taiwan.
    Huang JH; Tung CM
    Arch Gerontol Geriatr; 2006; 43(1):101-16. PubMed ID: 16280181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.